<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10390001</article-id><article-id pub-id-type="pmc">2363029</article-id><article-id pub-id-type="pii">6690344</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690344</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Reyes</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Garc&#x000ed;a-Castro</surname><given-names>I</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Esquivel</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hornedo</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cortes-Funes</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Solovera</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Alvarez-Mon</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1">Medicine/Immune System Diseases Oncology Service, Department of Medicine &#x02018;Principe de Asturias&#x02019;, University Hospital, Alcal&#x000e1; University, Carretera Madrid-Barcelona, Km 33.600, 28871 Alcal&#x000e1; de Henares, Madrid, Spain</aff><aff id="aff2">Medical Oncology Department, &#x02018;12 de Octubre&#x02019; University Hospital, Madrid, Spain</aff><aff id="aff3">Amgen, S.A. Barcelona, Spain</aff></contrib-group><pub-date pub-type="ppub"><month>4</month><year>1999</year></pub-date><volume>80</volume><issue>1-2</issue><fpage>229</fpage><lpage>235</lpage><history><date date-type="received"><day>12</day><month>02</month><year>1998</year></date><date date-type="rev-recd"><day>30</day><month>07</month><year>1998</year></date><date date-type="accepted"><day>09</day><month>09</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Granulocyte colony-stimulation factor (G-CSF) is a cytokine that selectively promotes growth and maturation of neutrophils and may modulate the cytokine response to inflammatory stimuli. The purpose of this study was to examine the effect of G-CSF on ex vivo peripheral blood mononuclear cell (PBMC) functions. Ten patients with breast cancer were included in a clinical trial in which r-metHuG-CSF was administrered daily for 5 days to mobilize peripheral blood stem cells. Ten healthy women were also included as controls. Our data show that G-CSF treatment induces an increase in peripheral blood leucocyte, neutrophil, lymphocyte and monocyte counts. We have found a modulation in the percentages of CD19+, CD45+CD14+, CD4+CD45RA+ and CD4+CD45RO+ cells in PBMC fractions during G-CSF treatment. We have also found a significant reduction in the proliferative response of PBMC to mitogenic stimulation that reverted 14 days after the fifth and the last dose of G-CSF. Furthermore, it was not associated with significant changes in the pattern of cytokine production. The mechanism of this immunoregulatory effect is probably indirect since G-CSF receptor has not been found in T lymphocytes. This mechanism and its potential clinical applications remain to be elucidated. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>G-CSF</kwd><kwd>breast cancer</kwd><kwd>autologous peripheral blood transplantation</kwd><kwd>T lymphocytes</kwd></kwd-group></article-meta></front></article>
